Correlation between alterations of inflammatory markers and treatment with atypical antipsychotics in patients diagnosed with bipolar affective disorder

IntroductionClinical evidences suggests that cerebral inflammatory processes are involved in the development of major affective disorders [1].Obvious correlations exist between changes of inflammatory markers such as acute-phase protein C (PCR) and VES, in patients with bipolar spectrum diagnosis [2].ObjectivesOur aim is demonstrating the correlations between changes of PCR and VES and pharmacological treatment with atypical antipsychotics in patients with acute bipolar disorder, highlighting a trend.MethodTwenty patients with bipolar disorder were assessed at the entrance (T0), after three weeks (T1) and after six weeks (T2) of hospitalization using specific rating scales and blood tests routines include PCR and VES.ResultsIs possible to appreciate a correlation between the affective phase of bipolar disorder and inflammatory markers with a proportional trend (Table 1).Discussion and conclusionThe scores obtained seem to confirm the effect of antipsychotic in both sense of psychiatric symptomatology reduction and in anti-inflammatory action.A confirmation of a correlation between the resolution of affective disorders and normalization of inflammatory markers confirm the intrinsic anti-inflammatory activity of such drug compounds [3].Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text

Inflammatory markers in mild cognitive impairment and anxiety disorders in middle-aged subjects with metabolic syndrome

European Psychiatry ◽

10.1016/j.eurpsy.2017.01.1373 ◽

2017 ◽

Vol 41 (S1) ◽

pp. S743-S743

Author(s):

V. Piotrovskaya ◽

N. Neznanov

Keyword(s):

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Anxiety Disorders ◽

Affective Disorders ◽

Inflammatory Markers ◽

Inflammatory Factors ◽

Blood Concentrations ◽

Co Morbidity ◽

Competing Interest ◽

Group B

Anxiety disorders are increasingly being associated with metabolic and cardiovascular burden, in contrast with depression; the role of inflammation in anxiety has sparsely been discussed. A number of reports of elevated inflammatory markers in mild cognitive impairment (MCI) suggest that inflammation may be a potential early marker of the pathological cascade associated with dementia. The aim of this study was to evaluate a possible association between peripheral blood concentrations of inflammatory factors in patients with MCI and mental processes such as, cognitive impairment and anxiety in obesity.Methods and resultsThe data collected from 271 patients with MetS according IDF criteria, (aged 30–60 years) have been analyzed. Lifetime diagnoses of depression (D), anxiety (A) was self-reported. Current D and A were confirmed by psychodiagnostic interview according to the criteria of ICD-10. All patients passed through: MMSE test, Wechsler memory scale, symbol coding and category Fluency test, scales HADS, HAM-A. Inflammatory markers included CRP, IL-6, IL-1 and TNF-α. Subjects were divided into group A–with D and/or A (139) and group B–without affective disorders (132). Using Mann–Whitney test significant connection between presence of MCI and high levels of inflammation is associated with simultaneous presence affective disorders. High correlations in subjects with A/D were between IL-6, IL-1 and MCI. In-group B, there was no significant correlations between inflammatory markers and MCI.ConclusionThere is link between affective disorders and levels of inflammatory markers. Increased levels of IL-6 and IL-1 provoke co-morbidity of MCI and depression or anxiety.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text

Do bipolar II and bipolar I disorder have different genotypes and why do we observe unipolar depression converting to bipolar II and then bipolar I?

European Psychiatry ◽

10.1016/j.eurpsy.2016.01.1136 ◽

2016 ◽

Vol 33 (S1) ◽

pp. S328-S328

Author(s):

M. Agius ◽

M. Fawcett ◽

R. Zaman

Keyword(s):

Bipolar Disorder ◽

Mood Disorder ◽

Recent Literature ◽

Bipolar Affective Disorder ◽

Unipolar Depression ◽

Bipolar Spectrum ◽

Clinical Genetic ◽

Bipolar Ii ◽

Competing Interest ◽

Staging Model

We review the recent literature in order to establish the importance of a spectrum for bipolar affective disorder, and that unipolar depression, bipolar II and bipolar I are discrete entities that may however evolve in sequence. We discuss clinical, genetic and neurobiological data which illustrate the differences between bipolar I and bipolar II. To fit the data we suggest a series of multiple mood disorder genotypes, some of which evolve into other conditions on the bipolar spectrum. Thence, we discuss the nature of the bipolar spectrum and demonstrate how this concept can be used as the basis of a staging model for bipolar disorder.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text

Antipsychotic in children and adolescents: Metabolic effects

European Psychiatry ◽

10.1016/j.eurpsy.2016.01.1282 ◽

2016 ◽

Vol 33 (S1) ◽

pp. S358-S358

Author(s):

M.D.L.C. Ramirez Dominguez ◽

I. Prieto Sánchez ◽

L. Hernandez Gonzalez ◽

S. Fernandez Leon ◽

M. Reina Dominguez

Keyword(s):

Bipolar Disorder ◽

Weight Gain ◽

Waist Circumference ◽

Metabolic Rate ◽

Atypical Antipsychotics ◽

Fasting Glucose ◽

Metabolic Effects ◽

Tight Control ◽

Competing Interest ◽

Early Schizophrenia

IntroductionThe use of antipsychotics in children is controversial, one of the considerations to take into account is the possible effect on the values of fasting glucose, prolactin or weight gain are very important.ObjectivesTo study the effect of these drugs on metabolic rate in children.MethodsWe measured the weight, waist circumference, fasting glucose and basal prolactin in 6 children at Children's Hospital in the province of Huelva, diagnosed with bipolar disorder and early schizophrenia, atypical antipsychotics before starting treatment and 6 months later.ResultsIn the provisional results it is found that a there is not a significant weight gain (less than 3%), no impairment of glucose and only in one case basal prolactin was elevated.ConclusionsThe use of atypical antipsychotics in children should be reserved when strictly necessary. Once established, keep tight control of metabolic parameters, although the data of our study coincide with the literature, do not produce significant alterations.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text

Epidemiological and Clinical Variables Related with the Predominant Polarity on Bipolar Disorder: A Systematic Review

European Psychiatry ◽

10.1016/j.eurpsy.2017.01.1899 ◽

2017 ◽

Vol 41 (S1) ◽

pp. S115-S116

Author(s):

J. García-Jiménez ◽

A. Porras-Segovia ◽

J.M. Gota-Garcés ◽

J.E. Muñoz-Negro ◽

L. Gutiérrez-Rojas

Keyword(s):

Bipolar Disorder ◽

Atypical Antipsychotics ◽

Mood Stabilizers ◽

Future Research ◽

Type I ◽

Inclusion Criteria ◽

Clinical Correlates ◽

History Of ◽

Competing Interest

IntroductionType I and type II classification of bipolar disorder (BD) may not provide useful information to the clinician regarding epidemiological and clinical correlates.New classifications have recently been proposed, such as the Predominant Polarity (PP) classification, which is based on the tendency of the patient to relapse in the manic (Manic Predominant Polarity [MPP]) or the depressive (Depressive Predominant Polarity [DPP]) poles along the course of the disease.ObjectivesTo explore the epidemiological and clinical correlates of PP.MethodsWe performed a search of the PubMed and Web of Science databases up to June 1st 2016, using the keywords “bipolar disorder”, “polarity” and “predominant polarity”.ResultsThe initial search identified 1598 articles. Only 17 articles met inclusion criteria. Factors associated with MPP are manic onset, history of drug abuse and a better response to atypical antipsychotics and mood stabilizers. Meanwhile DPP is associated with depressive onset, more relapses, longer acute episodes, and a higher risk of suicide. Moreover, delay until diagnosis, mixed episodes and comorbid anxiety disorders are more prevalent in DPP patients, whose treatment often involves quetiapine and lamotrigine.LimitationsFew prospective studies. Variability of results.ConclusionsPP classification may be useful for the clinical management of BD. Further research in this field is needed. Future research should use standardized definitions and more comparable methods.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text

Pharmacotherapy of acute psychotic states: The reason for benzodiazepines and valproic acid augmentation

European Psychiatry ◽

10.1016/j.eurpsy.2016.01.2287 ◽

2016 ◽

Vol 33 (S1) ◽

pp. S612-S612

Author(s):

A. Veraksa ◽

A. Egorov

Keyword(s):

Valproic Acid ◽

Mental Disorders ◽

Mental State ◽

Schizoaffective Disorder ◽

Affective Disorders ◽

Psychotic Disorders ◽

Bipolar Affective Disorder ◽

Schizophrenia Spectrum ◽

Icd 10 ◽

Competing Interest

Acute psychotic states (APS) usually are diagnosed as schizophrenia spectrum and affective disorders and make up about 45% of cases. The goal of the study was to elucidate the effect of benzodiazepines (BDZ) and valproic acid augmentation in the APS pharmacotherapy. The study was carried out on 102 inpatients diagnosed up to ICD-10 as schizophrenia (n = 24), acute and transient psychotic disorders (n = 40), other mental disorders due to brain damage and dysfunction and to physical disease (n = 17), schizoaffective disorder (n = 12), bipolar affective disorder (n = 9). Patients were randomized into four therapeutic groups:– benzodiazepines (BDZ);– one neuroleptic or combination of one neuroleptic and one BDZ (NBDZ);– combination of valproic acid with BDZ or neuroleptic (VBDZN);– polypragmasy (PP): from two drugs of one group up to four and more drugs at the same time.The mental state of the patients was evaluated daily and estimated before, weekly and after APS termination by BPRS and CGI scale. The APS in all groups lasted from 1 to 50 days (mean 11.4). The shortest duration of APS was In BDZ group – 4.7 days; in VBDZN and NBDZ, the duration was 7.0 and 7.4 days (P < 0.05); in PP group, the treatment lasted 24.5 days (P < 0.001). Before therapy, average BPRS rate was 43.5 ± 8.1, CGI – 6.2 ± 0.8; after APS, BPRS was 18.9 ± 2.1, CGI – 1.1 ± 0.3. All rates did not differ among subgroups. APS therapy by BDZ and its combination with neuroleptics and valproic acid was effective compared to the polypragmasy.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text

The epidemiology of bipolar affective disorder; a review of the literature and introduction to work in progress

Acta Neuropsychiatrica ◽

10.1017/s092427080003550x ◽

2000 ◽

Vol 12 (3) ◽

pp. 99-103 ◽

Cited By ~ 1

Author(s):

T. Lloyd ◽

P.B. Jones

Keyword(s):

Bipolar Disorder ◽

Affective Disorder ◽

Epidemiological Study ◽

Affective Disorders ◽

Bipolar Affective Disorder ◽

Review Of The Literature ◽

Epidemiological Research ◽

Psychological Treatments ◽

Bipolar Illness ◽

The Past

ABSTRACTThe past 20 years have seen much research into affective disorders, reflecting advances in both pharmacological and psychological treatments. However, there has been little basic epidemiological research into bipolar illness. This is particularly apparent regarding its basic occurrence and possible epigenetic causes. This presentation will attempt to bring together and integrate the available evidence regarding the basic epidemiology of bipolar disorder, define areas where further research is needed, and outline a large epidemiological study including bipolar affective disorder that has been supported by the Stanley Foundation.

Download Full-text

Anti-Inflammatory Activity of Miodesin™: Modulation of Inflammatory Markers and Epigenetic Evidence

Oxidative Medicine and Cellular Longevity ◽

10.1155/2020/6874260 ◽

2020 ◽

Vol 2020 ◽

pp. 1-11 ◽

Cited By ~ 1

Author(s):

Carlos Rocha Oliveira ◽

Rodolfo Paula Vieira

Keyword(s):

Dna Methylation ◽

Transcription Factor ◽

Inflammatory Response ◽

Inflammatory Markers ◽

Epigenetic Mechanism ◽

Macrophage Cell ◽

Inflammatory Processes ◽

Cox 2 ◽

Anti Inflammatory ◽

Cox 1

Purpose. To investigate the effects of a combined herbal medicine Miodesin™ on the inflammatory response of key cells involved in the acute and chronic inflammatory processes as well as the possible epigenetic involvement. Methods. After the establishment of the IC50 dose, the chondrocyte, keratinocyte, and macrophage cell lines were pretreated for 2 hours with Miodesin™ (200 μg/mL) and stimulated with LPS (1 μg/mL) for 24 hours. The supernatant was used to measure the levels of cytokines (IL-1β, IL-6, IL-8, and TNF-α) and chemokines (CCL2, CCL3, and CCL5), and the cells were used to extract the mRNA for the transcription factor (NF-κβ), inflammatory enzymes (COX-1, COX-2, PLA2, and iNOS), and chemokines (CCL2, CCL3, and CCL5). Results. Miodesin™ inhibited the release of LPS-induced cytokines (IL-1β, IL-6, IL-8, and TNF-α; p<0.01) and chemokines (CCL2, CCL3, and CCL5; p<0.01) and the expression of the transcription factor (NF-κβ; p<0.01), inflammatory enzymes (COX-1, COX-2, PLA2, iNOS; p<0.01), and chemokines (CCL2, CCL3, and CCL5; p<0.01). In addition, the evaluation of epigenetic mechanism revealed that Miodesin™ did not induce changes in DNA methylation, assuring the genetic safeness of the compound in terms of the inflammatory response. Conclusions. Miodesin™ presents anti-inflammatory properties, inhibiting hyperactivation of chondrocytes, keratinocytes, and macrophages, involving epigenetics in such effects.

Download Full-text

Assessment of Serum IL-4, 15d-PGJ2, PPAR Gamma Levels in Patients with Bipolar Disorder

European Psychiatry ◽

10.1016/j.eurpsy.2017.01.240 ◽

2017 ◽

Vol 41 (S1) ◽

pp. S75-S75

Author(s):

G. Erzin ◽

Ç. aydemir ◽

R. yüksel ◽

E. tatlıdil ◽

B. Çakır ◽

...

Keyword(s):

Bipolar Disorder ◽

Demographic Data ◽

Depression Scale ◽

Ppar Gamma ◽

Hamilton Depression Scale ◽

Healthy Controls ◽

Young Mania ◽

Endogenous Factors ◽

Anti Inflammatory ◽

Competing Interest

IntroductionMany hypotheses have been proposed about development of bipolar disorder including inflammatory processes due to the external and endogenous factors. There are strong evidences that immunological dysfunction is present in bipolar disorder. In the pathophysiology of bipolar disorder, there are many data that support the inflammatory hypothesis.ObjectivesIn this study, to clarify the etiology of bipolar disorder, based on the inflammatory process hypothesis, it is aimed to measure and evaluate serum 15d-PGJ2 and PPARγ, anti-inflammatory cytokine IL-4 levels in patients with bipolar disorder.MethodsThis study was performed at Ankara Numune Training and Research Hospital. Ninety-five patients are included in the study that were in their mania or remission periods and meet the DSM-V criteria for bipolar disorder. Forty-four healthy volunteers are included in the study as well. Serum IL-4, 15d-PGJ2, PPARγ levels are measured in both groups. Young Mania Scale, Hamilton Depression Scale, demographic data form were given to patient group.ResultsIn our study, 15d-PGJ2, PPARγ levels were found statistically significantly lower in patients with bipolar disorder compared to healthy controls.ConclusionThere are differences in anti-inflammatory prostaglandin levels in patients with bipolar disorder who are in their mania period when compared to healthy controls and patients in their remission period. This does not show any significance according to smoking and gender. This implies that inflammation markers could be a good candidate to determine trait markers, which will provide an insight for preventing patient from mania period or prognosis after the diagnosis of bipolar disorder.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text